Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

39.53 +0.22 (+0.56%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited Ordinary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

35 36 Next >

Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet ↗

January 29, 2025

Via Benzinga

Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday? ↗

January 29, 2025

Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET.

Via Benzinga

Topics Economy Government

Stocks Scatter As Investors Prepare For Fed Remarks ↗

January 29, 2025

Stocks are mixed this afternoon, as investors await an interest rate update from the Federal Reserve's first policy meeting of 2025.

Via Talk Markets

Topics Economy Stocks / Equities

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗

January 27, 2025

Via Benzinga

Peering Into Teva Pharmaceutical Indus's Recent Short Interest ↗

January 27, 2025

Via Benzinga

Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings ↗

January 29, 2025

Via Benzinga

Teva Pharmaceutical Posts Lower Revenue. Stock Slips. ↗

January 29, 2025

Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.

Via Investor's Business Daily

Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On? ↗

January 29, 2025

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,...

Via Benzinga

Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 29, 2025

Via Benzinga

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

January 29, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Earnings Scheduled For January 29, 2025 ↗

January 29, 2025

Via Benzinga

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗

January 28, 2025

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 27, 2025

From Alvotech

Via GlobeNewswire

FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug ↗

January 23, 2025

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

Via Benzinga

Promising Signs: TEVA PHARMACEUTICAL-SP ADR Setting the Stage for a Breakout. ↗

January 23, 2025

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) has a good technical rating of 10 out of 10 and could possibly break out.

Via Chartmill

Teva Challenges Drug Price Law's Impact On Innovation, Generics ↗

January 17, 2025

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance.

Via Benzinga

Topics Economy

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday ↗

January 17, 2025

Via Benzinga

Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

January 13, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

January 10, 2025

From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.

Via GlobeNewswire

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical ↗

January 09, 2025

Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.

Via Benzinga

Topics Intellectual Property

IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva ↗

January 08, 2025

One of Catalyst's key products has protection against a knockoff from Teva until 2035.

Via Investor's Business Daily

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗

January 06, 2025

CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.

Via Benzinga

Topics Lawsuit

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug ↗

January 06, 2025

Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives.

Via Benzinga

Tesla, Avinger, Jet.Ai, Teva, And Netflix: Why These 5 Stocks Are On Investors' Radars Ahead Of Christmas ↗

December 24, 2024

Wall Street experienced a positive start to the Santa Rally season, with all major indices and sectors closing higher in the session ahead of Christmas.

Via Benzinga

Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next ↗

December 24, 2024

Druckenmiller's Duquesne Family Office sold Nvidia and Palantir stocks while increasing stake in Teva Pharmaceutical, signaling a shift in investment focus.

Via Benzinga

Topics Artificial Intelligence

Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025 ↗

December 24, 2024

Duquesne Family Office's chief is cashing in his chips on two leading artificial intelligence (AI) stocks in favor of a drugmaker whose shares are up by 112% for the year.

Via The Motley Fool

Topics Artificial Intelligence

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 23, 2024

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.